News
BVNKF
22.56
NaN%
--
Weekly Report: what happened at BVNKF last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at BVNKF last week (0415-0419)?
Weekly Report · 04/22 11:19
Weekly Report: what happened at BVNKF last week (0408-0412)?
Weekly Report · 04/15 11:10
Weekly Report: what happened at BVNKF last week (0401-0405)?
Weekly Report · 04/08 11:16
Weekly Report: what happened at BVNKF last week (0325-0329)?
Weekly Report · 04/01 11:13
Weekly Report: what happened at BVNKF last week (0318-0322)?
Weekly Report · 03/25 11:16
Weekly Report: what happened at BVNKF last week (0311-0315)?
Weekly Report · 03/18 11:15
Weekly Report: what happened at BVNKF last week (0304-0308)?
Weekly Report · 03/11 11:11
Bavarian Nordic A/S GAAP EPS of DKK19.20, revenue of DKK17.06B
Seeking Alpha · 03/06 14:09
Weekly Report: what happened at BVNKF last week (0226-0301)?
Weekly Report · 03/04 11:14
Weekly Report: what happened at BVNKF last week (0219-0223)?
Weekly Report · 02/26 11:27
Bavarian Nordic pulls plug on cancer vaccine program
Seeking Alpha · 02/21 20:09
Weekly Report: what happened at BVNKF last week (0212-0216)?
Weekly Report · 02/19 11:29
Weekly Report: what happened at BVNKF last week (0205-0209)?
Weekly Report · 02/12 11:19
Weekly Report: what happened at BVNKF last week (0129-0202)?
Weekly Report · 02/05 11:27
Weekly Report: what happened at BVNKF last week (0122-0126)?
Weekly Report · 01/29 11:16
Weekly Report: what happened at BVNKF last week (0115-0119)?
Weekly Report · 01/22 11:20
Weekly Report: what happened at BVNKF last week (0108-0112)?
Weekly Report · 01/15 11:16
Weekly Report: what happened at BVNKF last week (0101-0105)?
Weekly Report · 01/08 11:20
Weekly Report: what happened at BVNKF last week (1225-1229)?
Weekly Report · 01/01 11:14
More
Webull provides a variety of real-time BVNKF stock news. You can receive the latest news about Bavarian Nordic through multiple platforms. This information may help you make smarter investment decisions.
About BVNKF
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.